Antigenic Switching of Hepatitis B Virus by Alternative Dimerization of the Capsid Protein  by DiMattia, Michael A. et al.
Structure
ArticleAntigenic Switching of Hepatitis B Virus
by Alternative Dimerization of the Capsid Protein
Michael A. DiMattia,1,2 Norman R. Watts,3 Stephen J. Stahl,3 Jonathan M. Grimes,1,4 Alasdair C. Steven,2,*
David I. Stuart,1,4,* and Paul T. Wingfield3
1Division of Structural Biology, Henry Wellcome Building for Genomic Medicine, University of Oxford, Roosevelt Drive,
Headington OX3 7BN, UK
2Laboratory of Structural Biology Research
3Protein Expression Laboratory
National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health, Bethesda, MD 20892, USA
4Diamond Light Source, Didcot OX11 0DE, UK
*Correspondence: stevena@mail.nih.gov (A.C.S.), dave@strubi.ox.ac.uk (D.I.S.)
http://dx.doi.org/10.1016/j.str.2012.10.017SUMMARY
Chronic hepatitis B virus (HBV) infection afflicts
millions worldwide with cirrhosis and liver cancer.
HBV e-antigen (HBeAg), a clinical marker for disease
severity, is a nonparticulate variant of the protein
(core antigen, HBcAg) that forms the building-blocks
of capsids. HBeAg is not required for virion pro-
duction, but is implicated in establishing immune
tolerance and chronic infection. Here, we report the
crystal structure of HBeAg, which clarifies how the
short N-terminal propeptide of HBeAg induces a radi-
cally altered mode of dimerization relative to HBcAg
(140 rotation), locked into place through formation
of intramolecular disulfide bridges. This structural
switch precludes capsid assembly and engenders
a distinct antigenic repertoire, explaining why the
two antigens are cross-reactive at the T cell level
(through sequence identity) but not at the B cell level
(through conformation). The structure offers insight
into how HBeAg may establish immune tolerance
for HBcAg while evading its robust immunogenicity.
INTRODUCTION
Hepatitis B virus (HBV) infection remains a major source of
acute and chronic liver disease worldwide. More than 360million
people have chronic HBV infection, which results in one million
deaths annually, primarily due to cirrhosis and liver cancer.
Over the four decades since the discovery of HBV, striking
advances have beenmade in our understanding of themolecular
biology, immunology, and pathogenesis of infection. However,
certain aspects of HBV biology remain elusive. One such con-
cern is the structure of the viral e-antigen (HBeAg), as well as
its functional role in HBV infection. While HBeAg has no demon-
strated role in the viral replication cycle (Chang et al., 1987; Chen
et al., 1992; Schlicht et al., 1987), the antigen has long been a key
clinical marker for viral replication, infectivity, disease severity,
and response to treatment (Elgouhari et al., 2008). Furthermore,
HBeAg (or an equivalent) exists in all members of the Hepadna-Structure 21, 13viridae family, suggesting an evolutionarily conserved and there-
fore important function (Revill et al., 2010).
The HBV capsid protein (HBcAg; core antigen) comprises
a 149-residue assembly domain and a 34-residue arginine-rich
domain (Figure 1A). The assembly domain forms dimers with
a central four-helix bundle and flanking a helices that assemble
into icosahedral capsids of two sizes, with the four-helix bundles
projecting as spikes (Packianathan et al., 2010; Wynne et al.,
1999). HBeAg consists of the ten N-terminal residues (the pro-
peptide: SKLCLGWLWG) appended to the assembly domain
with the C terminus at residue 149 (Figure 1A) (Ou et al., 1986;
Standring et al., 1988; Takahashi et al., 1983). Translation of the
C gene from an alternative upstream start codon yields a protein
with a 29-residue signal peptide that routes it to the endoplasmic
reticulum, where it is processed to the 10-residue propeptide
(Standring et al., 1988). However, despite possessing an intact
assembly domain, HBeAg does not assemble into capsids and
is secreted by infected liver cells in nonparticulate form.
Much evidence suggests that HBeAg can modulate the host
immune response to favor chronic infection following perinatal
transmission (the most common form of HBV transmission
worldwide) and prevent severe liver injury during adult infections
(Chen et al., 2004, 2005; Milich and Liang, 2003; Ou, 1997;
Visvanathan et al., 2007; Yang et al., 2006). The epidemiologic
evidence is persuasive: more than 90% of infants born to
mothers who are HBeAg-positive HBV carriers also develop
chronic infection, whereas those born to HBeAg-negative
mothers rarely progress to chronicity (Terazawa et al., 1991).
While the molecular mechanisms underlying these processes
are unclear, it has been shown that HBeAg can downregulate
the inflammatory response directed at HBcAg, while itself
averting robust immunogenicity (Chen et al., 2004, 2005; Milich
and Liang, 2003). Further, HBeAg (but not HBcAg) can cross
the placenta from mother to child (Scho¨del et al., 1993), con-
sistent with data suggesting that HBeAg may induce clonal
tolerance against HBcAg and HBeAg in utero (Chen et al.,
2004; Milich et al., 1990). While the connection between HBeAg
and chronic infection is not fully understood, infections with HBV
strains that do not express HBeAg (due to mutation in the pre-C
region) lead to a much higher frequency of fulminant hepatitis
and acute liver failure (Fagan et al., 1986; Liang et al., 1991). In
these circumstances, the lack of immune modulation by HBeAg3–142, January 8, 2013 ª2013 Elsevier Ltd All rights reserved 133
Figure 1. Structure of HBeAg
(A) Domain schematic of HBeAg and HBcAg, which share the assembly domain but differ in that HBeAg retains the N-terminal propeptide (P; magenta) and lacks
the RNA-binding arginine-rich domain (AR). The linker region (L) is present, but disordered in crystal structures of both antigens.
(B) Ribbon diagram of HBeAg monomer, colored blue to red from N- to C terminus, with the propeptide (magenta) shown forming an intramolecular disulfide
(yellow) between C(7) and C61. Secondary structure elements are entirely a-helical (a1-a5); propeptide is irregular coil.
(C and D) Ribbon diagram of the HBeAg dimer; viewed axially. Front subunit is colored according to the scheme in (A); rear subunit is colored gray. Hairpins of the
a3b and a4a helices from each subunit form the dimer interface, supported by the propeptides intercalated between them.
(E and F) Superposition of HBeAg and HBcAg monomers (thick and thin ribbon, respectively) (Packianathan et al., 2010; Wynne et al., 1999).
(G) Crystal asymmetric unit depicts HBeAg dimer complexed with two Fab e6molecules (shown asmolecular surface) binding at a5 and the C-terminal loop (red).
See also Figure S1.
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Crystal Structure of Hepatitis B Virus e-Antigenis thought to lead to an unregulated and overwhelming
immune response to HBcAg. To develop a fundamental under-
standing of the functional distinction between HBcAg and
HBeAg, knowledge of their respective structures is essential.
HBcAg and HBeAg have been viewed as serologically distinct
(Conway et al., 1998; Imai et al., 1982; Salfeld et al., 1989).
However, a recent analysis of a panel of six monoclonal anti-
bodies found four to cross-react with both antigens, albeit with
markedly differing affinities, and one each specific for HBcAg
and HBeAg (Watts et al., 2010). The HBeAg-specific Fab e6
was found to form a stable complex with the recombinantly
expressed HBeAg dimer. We have now crystallized the complex
and determined its structure. Here, we develop this information
to explore the long-standing question of how the 10-residue pro-
peptide retained by HBeAg transforms the protein’s propensity
to assemble, its antigenic character, and its apparent ability to
modulate the immune response to favor viral persistence.134 Structure 21, 133–142, January 8, 2013 ª2013 Elsevier Ltd All rigRESULTS
Here, we report the crystal structure of recombinantly expressed
HBeAg and Fab e6 to a resolution of 3.3 A˚, solved by molecular
replacement, exploiting a 2.5 A˚ structure for the Fab e6 alone,
which we determined separately. The Fab fragment facilitated
crystallization (Figure S1 available online). Even at 3.3 A˚ resolu-
tion, the key features of HBeAg are firmly established (Table 1;
Figure S1).
HBeAg and HBcAg Monomer Folds Are Similar
The structure shows HBeAg as a dimer with each subunit bound
to an e6 Fab (Figure 1G), consistent with the finding that HBeAg
is dimeric (Steven et al., 2005) and the reported stoichiometry of
the complex (Watts et al., 2010). Overall, the monomer fold is
essentially the same as that of HBcAg: helices a1 and a2 and
the loop between them encircle an amphipathic hairpin of kinkedhts reserved
Table 1. Data Collection and Refinement Statistics
Crystal Data HBeAg- e6 Fab Complex Fab e6
Space group Triclinic P1 Monoclinic C2
Unit cell parameters (A˚, ) a = 66.7, b = 75.8, c = 88.7, a = 124.1, b = 68.2, c = 236.6,
a = 96.8, b = 103.8, g = 116.0 a = 90.0, b = 96.3, g = 90.0
HBeAg dimer molecules per ASU 1 0
e6 Fab molecules per ASU 2 4
VM (A˚
3 Da1) 2.92 2.60
Solvent content (%) 57.9 52.7
Data Collection Statistics
Resolution (A˚) 46.2–3.34 (3.43–3.34) 31.1–2.52 (2.58–2.52)
Rwork (%) 11.6 (73.7) 9.6 (91.1)
I/s(I) 6.4 (1.0) 7.7 (1.3)
Completeness (%) 92.6 (88.8) 99.5 (99.6)
Mean multiplicity 1.8 (1.6) 3.4 (3.5)
Refinement Statistics
No. of total reflections 34,840 223,579
No. of unique reflections 19,664 66,469
No. of reflections used in refinement 19,651 66,468
Rwork / Rfree (%) 23.3/23.4 18.1/21.9
Reflections used for Rfree (jFoj > 0) (%) 5.0 5.0
Ramachandran Plot (%)
Most favored 96.0 96.9
Allowed 3.7 3.0
Outliers 0.3 0.1
No. of protein atoms 9,076 13,480
Average B-factor (A˚2) 111 62
Wilson B-factor (A˚2) 76 58
Rmsds
Bond lengths (A˚) 0.008 0.010
Bond angles () 1.19 1.27
B-factor of bonded atoms (A˚2) 0.8 1.7
NCS related HBeAg coordinates (A˚) 0.03 –
NCS related HBeAg B-factors (A˚2) 6.6 –
NCS related Fab e6 coordinates (A˚) 0.09 0.64
NCS related Fab e6 B-factors (A˚2) 7.5 14.1
Targeted Refine. Fab coords (A˚) 0.50 –
Targeted Refine. Fab B-factors (A˚2) 13.0 –
Highest resolution shell is shown in parentheses. Rwork is calculated taking account of disordered, unmodeled portions of the structure (Bricogne et al.,
2011). Rfree is calculated identically to Rwork but corresponds to 5%of data omitted from refinement for cross-validation. The e6 Fab andHBeAg-e6 Fab
structures were each determined from data derived from a single crystal.
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Crystal Structure of Hepatitis B Virus e-Antigenhelices (a3 and a4), followed by a5 and a proline-rich C-terminal
loop (Figure 1B) (Packianathan et al., 2010; Wynne et al., 1999).
The respective assembly domains superpose with a root-mean-
square deviation of 1.6 A˚ for the 141 corresponding Cas, with
variability most affecting the spike apex, the loop between a2
and a3a, and the C-terminal loop. However, the greatest differ-
ence is the propeptide in HBeAg (Figures 1E and 1F) which
adopts a loop structure that forms an intramolecular disulfide
bond between C(7) and C61 (Figure 1B). These disulfides in
HBeAg (two per dimer)—versus the single intermolecular
C61-C61 disulfide that stabilizes the HBcAg dimer—have beenStructure 21, 13reported to be critical for the secretion of HBeAg (Nassal and
Rieger, 1993; Scho¨del et al., 1993; Wasenauer et al., 1992).
HBeAg and HBcAg Form Radically Different Dimers
HBcAg dimerizes through the pairing, in parallel, of two helical
hairpins to form a four-helix bundle (Figure 2A, right). The inter-
face between the hairpins is largely hydrophobic and rather flat
(Packianathan et al., 2010; Wynne et al., 1999). Flanking the
four-helix bundle are salt bridges and hydrogen bonds between
the charged, polar residues of the N-terminal strand and the
a2-a3 loop. In contrast, in HBeAg, the propeptide loop makes3–142, January 8, 2013 ª2013 Elsevier Ltd All rights reserved 135
Figure 2. Comparison of HBeAg and HBcAg
Structures
(A) The conformational switch. Propeptide density
sterically interferes to block formation of the
HBcAg dimer interface, allowing HBeAg to form
a different dimer interface using the same
surfaces, but 140 rotated. The gray surface-
rendered subunits of each dimer are shown in the
same orientation, providing a frame of reference in
which the relative rotation between the colored
ribbon subunits is evident.
(B) Dimer interface comparison. HBeAg employs
molecular mimicry to form a similar, hydrophobic
dimer interface with a3/a4 hairpins, in an inverted
orientation relative to HBcAg. Arrays of hydro-
phobic groups, and even the positioning of
aromatics such as Y88 and W71 in HBcAg are
replicated by different residues, such as W71 and
W(4) in HBeAg.
(C) Thepropeptidemediates hydrophobic contacts
within elements that would otherwise already be
buried in the context of the HBcAg dimer.
See also Figure S2.
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Crystal Structure of Hepatitis B Virus e-Antigenstabilizing hydrophobic contacts with the central part of the
a3-a4 surface of its own polypeptide chain, where it sterically
blocks the formation of an HBcAg-like dimer (Figure 1C).
Instead, HBeAg dimerization involves (part of) the same molec-
ular surfaces but with a relative rotation of 140 between the
hairpins (Figure 2A, left). In HBeAg, the two a3b helices are
nearly antiparallel and make an array of hydrophobic con-
tacts as they pair to form a ridge in the dimer interface. In con-
trast, the a4a helices do not interact with each other, but
instead interact with the exterior surface of the partner’s pro-
peptide, also via hydrophobic contacts. In the view along the
2-fold axis of the HBeAg dimer (Figure 1D), it is apparent that136 Structure 21, 133–142, January 8, 2013 ª2013 Elsevier Ltd All rights reservedthe a4a helices are too far apart to
interact and that the intercalated propep-
tide loop completes the dimer interface.
Molecular Mimicry between the
HBeAg and HBcAg Dimer Interfaces
In the HBeAg dimer is a constellation of
hydrophobic residues that mimics many
of the hydrophobic interactions at the
HBcAg dimer interface. For example,
propeptide residues W(4), L(3), W(2)
in HBeAg make dimer contacts analo-
gous to those of L68, W71, and L76 in
HBcAg (Figure 2B). These three propep-
tide residues form a hydrophobic cluster
accounting for > 50% of the surface
area buried at the interface. Along the
a3b ridge, another hydrophobic patch
involves L68, V72, L76, and W71 of both
dimer subunits, whereas in HBcAg these
residues interact with L84, Y88, M93,
and V95 (Figure 2B). However, the HBeAg
dimer interface is much smaller than that
of HBcAg, burying 1640 versus 3970 A˚2,has poorer shape complementarity (0.61 versus 0.70) (Lawrence
and Colman, 1993), and makes fewer predicted hydrogen
bonds, consistent with biophysical data showing that the HBeAg
dimer is stable but less so than the HBcAg dimer (melting
temperatures 51C and 65C, respectively) (Watts et al., 2011).
Despite this difference in stability, the propeptide introduces
steric hindrance that blocks HBeAg from adopting the HBcAg
conformation. Hydrophobic regions that are buried in the HBcAg
dimer—but would otherwise be exposed in the HBeAg confor-
mation—are shielded by the propeptide (Figure 2C). This leaves
many of the flanking polar residues that participate in dimer-
dimer capsid interactions in HBcAg, exposed in HBeAg.
Figure 3. Centrifugation and EM Experi-
ments on HBeAg in Reduced and Oxidized
Forms
(A and B) Sedimentation velocity analyses per-
formed on (A) oxidized and (B) reduced HBeAg
using a Beckman Optima XL-I analytical ultra-
centrifuge, absorption optics, an An-60 Ti rotor,
and standard double-sector centerpiece cells.
Measurements at 20C were taken at 45,000 rpm
for 3 hr with data collection at 10min intervals. The
profiles show protein absorbance at 280 nm as
a function of radial distance.
(C and D) Negative-staining EM of assembly
products of (C) oxidized and (D) reduced HBeAg.
Both samples, in PBS ± DTT, were buffer-
exchanged into TBS to avoid precipitation. Both
images are at the same magnification; capsids are
32 nm in diameter.
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Assemble into Capsids
Previous work has shown that, under certain in vitro conditions,
HBeAg can be induced to form capsids (Watts et al., 2011). On
the other hand, the crystal structure of HBeAg reveals a confor-
mation that is incompatible with capsid assembly. Given the
presence of the HBeAg-specific disulfide bridge, we hypothe-
sized that the protein’s oxidation state may affect its state of
assembly. To test this idea, HBeAg samples were analyzed by
analytical ultracentrifugation sedimentation velocity (AUC) using
material verified to be dimeric and completely oxidized, as well
as the same material but pre-treated with reductant. Oxidized
HBeAg remains dimeric (single homogenous sedimenting
boundary 2.5S), whereas reduced HBeAg contains about
30% of a fast-sedimenting component (>40S), consistent with
high-molecular weight protein (Figures 3A and 3B). Negative-
stain electron microscopy (EM) confirmed the presence of
capsids in reductant-treated samples together with some other
polymeric structures, but there was no sign of capsids in the
oxidized sample (Figures 3C and 3D). Consistent with these
results, it has been shown that an HBeAg mutant in which
C(7) is substituted to A forms dimers with the same intermolec-
ular C61-C61 disulfide bond seen in HBcAg dimers. This change
increases the protein’s melting temperature to 63C (similar to
the value observed for HBcAg) (Watts et al., 2011), suggesting
that in the absence of the C(7)-C61 disulfide bridge, the pro-
peptide is displaced, allowing HBeAg to adopt an HBcAg-like
conformation. This inference is supported by the observation
that HBeAg can form capsid-like particles (Watts et al., 2011),Structure 21, 133–142, January 8, 2013and we have now demonstrated that
this occurs only when the disulfide is dis-
rupted by reduction (Figure 3).
DISCUSSION
It has been four decades since the first
description of HBeAg (Magnius and
Espmark, 1972), and three since its isola-
tion fromserumand the discovery that it is
closely related to HBcAg (Ferns andTedder, 1984; MacKay et al., 1981). Despite this close relation,
the two antigens have proved to have very different biophysical
and functional properties (Chen et al., 2004, 2005; Milich and
Liang, 2003; Nassal and Rieger, 1993; Steven et al., 2005;
Wasenauer et al., 1992). The crystal structure of HBeAg reveals
that its subunit has much the same fold as that of HBcAg (Wynne
et al., 1999) but a radically different mode of dimerization, which
explains the profound biophysical and antigenic differences
between the two proteins. While there are many examples of
alternative dimer interfaces in protein crystal packing, the
phenomenon of alternative physiologically relevant modes of
dimerizationhas few if anyprecedents (but seeSilva´n et al., 2012).
The Propeptide Sterically Hinders Formation
of an HBcAg-like Dimer
The HBeAg structure shows how the presence of the propeptide
prevents formation of the HBcAg dimer interface by ordering
against the inner a3-a4 hairpin surface and sterically blocking
dimerization (Figure 2C). Remarkably, the HBeAg monomer
circumvents thissteric obstaclebyusingpartsof thesamemolec-
ular surfaces to form an alternative dimer, but with the subunits
rotated 140 relative to their orientation in HBcAg (Figure 2A).
In this altered conformation, bulky, hydrophobic residues W(4),
L(3), andW(2) in the propeptide shield hydrophobic groups on
the opposing subunit’s surface that would otherwise be exposed
(Figure 2B). Further, intercalation of the two propeptides between
the a3-a4 hairpins of opposing subunits completes the HBeAg
dimer interface, mimicking molecular interactions that take place
in HBcAg. The importance of the propeptide is corroborated byª2013 Elsevier Ltd All rights reserved 137
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Crystal Structure of Hepatitis B Virus e-Antigenthe near complete conservation of its sequence among the
mammalian Hepadnaviridae (Revill et al., 2010) (Figure S2).
The C(–7)-C61 Disulfide Bridge Is Essential
for the HBeAg Dimer Structure
Our data (above) imply that the C(7)-C61 intramolecular disul-
fide bridge present in HBeAg is crucial for maintaining the
observed propeptide conformation. Evidence includes the pro-
peptide’s lack of secondary structure and disorder of propeptide
residues S(10), K(9), L(8). We tested the influence of this
disulfide on HBeAg structure by analyzing oxidized and reduced
HBeAg samples by analytic ultracentrifugation and EM (Fig-
ure 3). When the disulfide bridge is disrupted, the HBeAg
subunits revert to an HBcAg-like mode of association, and are
able to form capsids. This reversion is consistent with calorim-
etry data indicating that the HBcAg dimer is more stable than
the (oxidized) HBeAg dimer (melting temperature of 65C versus
51C) (Watts et al., 2011). This conclusion as to relative stability is
further supported by the HBeAg dimer interface being markedly
smaller than that of HBcAg (1,640 versus 3,970 A˚2). We conclude
that once the disulfide is formed, it locks the propeptide into
place. Alternatively, when it is disrupted, the subunits revert to
the thermodynamically favored HBcAg conformation. The
HBeAg dimer is assembly-incompetent because the subunits
are arranged such that the inter-dimer contacts necessary for
capsid assembly—between adjacent C-terminal loops and
a2-a3 arms—cannot form (Ceres and Zlotnick, 2002).
Molecular Switching Between HBeAg and HBcAg
Explains the Observed Differences in Antigenicity
The lack of a high-resolution structure for HBeAg has hampered
understanding of its antigenicity. Some antibodies are cross-
reactive between HBcAg and HBeAg, while others recognize
only one, and the antigens are not considered cross-reactive
at the B cell level in natural infection (Baumeister et al., 2000;
Imai et al., 1982; Milich and Liang, 2003; Salfeld et al., 1989;
Steven et al., 2005; Watts et al., 2010). The human antibody
response to HBcAg is primarily conformational and directed
against the outer part of the capsid spike (residues 74-89) as
well as the floor of the capsid around the threefold axis (Ferns
and Tedder, 1986; Kandiah et al., 2012; Salfeld et al., 1989).
Cryo-EM analyses of Fab-labeled capsids have characterized
the epitopes of six murine anti-HBcAg monoclonal antibodies—
allbutone (312), conformational—onthecapsidsurface (Figure4A;
reviewed in Steven et al., 2005). We have now mapped these
epitopes onto the HBeAg crystal structure (Figures 4B and S3).
HBcAg epitopes are typically juxtapositions of two or more loops
from different subunits or discontinuous regions of the same
subunit. In HBeAg, these loops are moved apart, leaving single
loops with reduced affinity. For antibodies 3105 and F11A4, the
reduction is by two and three orders of magnitude, respectively
(Watts et al., 2010). Furthermore, the epitope of anti-HBcAg anti-
body 3120 maps to the capsid floor around the 3-fold axis, bridg-
ing between two adjacent dimers (Figure 4A). Such floor-binding
antibodies do not bind to HBeAg, because formation of their
composite epitope requires capsid assembly (Figure 4B). In addi-
tion to epitopes shared with HBcAg, the HBeAg structure reveals
a large, accessible molecular surface that is likely to present anti-
bodydeterminantsunique toHBeAg.Thissurfaceexposes regions138 Structure 21, 133–142, January 8, 2013 ª2013 Elsevier Ltd All rigthat are inaccessible in assembled capsids, including the epitope
of thee6antibodyused in this study (binding toa5and theadjacent
C-terminal loop) (Figures 1G and S4), as well as new surfaces
created from the rearrangement of the helical hairpins.
Alternative Dimerization of HBcAg and HBeAg May
Underlie Their Apparent ‘‘Split’’ Immune Tolerance
HBcAg and HBeAg appear to be regulated independently by the
immune system, resulting in a significantly more immunogenic
(HBcAg) or tolerogenic (HBeAg) T cell response (Chen et al.,
2005; Milich et al., 1997a, 1997b; Milich and McLachlan, 1986;
Vanlandschoot et al., 2003). One aspect of this regulation is the
observation that HBcAg, but not HBeAg, can directly bind to
and activate B cells without the requirement for T cell support,
leading to a robust humoral and cytotoxic T cell response
(Lazdina et al., 2001;Milich et al., 1997a, 1997b;Milich andMcLa-
chlan, 1986). How this takesplace is unclear, although it has been
proposed that structural differences between the antigens are
responsible: the array of spike-resident epitopes on the capsid
surface (Figure 4A) may crosslink B cell receptors, activating
the B cells and initiating the cascade (Milich et al., 1997a,
1997b; Vanlandschoot et al., 2003; Wu et al., 2012). Because
HBeAg has a conformation that precludes capsid formation and
the clustering of B cell receptors, this may explain its inability to
activate B cells as well as its reduced immunogenicity compared
to HBcAg. However, it is known that HBcAg and HBeAg remain
cross-reactive at the T cell level, due to sequence identity (as
T cell activation involves MHC-presentation of short antigenic
peptides) (Milich and Liang, 2003). This duality may engender
an immune response in which T cell cross-reactivity is necessary
for inducing clonal tolerance to HBcAg (Chen et al., 2004, 2005;
Vanlandschoot et al., 2003), while the antigenic switching allows
HBeAg to avert the robust immune response that HBcAg elicits.
The molecular switch that relates the pairing of assembly
domains in HBeAg andHBcAg explainsmany of the fundamental
biophysical and antigenic differences between them (Figure 5)
and has implications for their respective immunological proper-
ties in the context of chronic HBV infection. There are probably
other levels of regulation in which HBeAg also takes part to
establish chronicity, including, for example, modulation of the
innate and adaptive immune responses via direct interaction
with host immune proteins (Lang et al., 2011; Purvina et al.,
2012; Visvanathan et al., 2007; Yang et al., 2006). A long-
standing perception of HBeAg has been that it is a monomeric
protein with an N-terminal propeptide that happens to be requi-
site for HBeAg functionality. Our data have shown that HBeAg
is not a monomer, but a dimer, and that the crucial feature of
its propeptide is its strategically positioned Cys residue that
dictates the structure of the HBeAg dimer. This structure may,
we conjecture, confer an ability to interact directly with host
immune proteins in ways that HBcAg cannot. The crystal struc-
ture now provides a framework upon which further study can
fully elucidate the role of HBeAg in HBV persistence.EXPERIMENTAL PROCEDURES
Protein Preparation and Crystallization
We used the construct Cp(10)149, C48A, C107A, and refer to it here as
HBeAg although it differs fromwild-type HBeAg in having two Ala substitutionshts reserved
Figure 4. Antigenicity of HBeAg and HBcAg
(A) Partial surface of an HBcAg capsid with the
epitopes for several anti-HBc/eAg antibodies
mapped in colors. Most of these epitopes reside
around the spike tips, either on one subunit of the
dimeric spike or bridging both subunits. Mab 3120
binds to the floor around the threefold and fivefold
symmetry axes.
(B) The same epitopes (matched colors) mapped
on the HBeAg dimer. Affinity constants deter-
mined by surface plasmon resonance (Kd values;
Watts et al., 2010) are given, where available. A
2–3 order of magnitude drop is observed for Mabs
F11A4 and 3105 on HBeAg relative to HBcAg,
consistent with the constituent loops, which are
close together on HBcAg, being well separated on
HBeAg.
See also Figures S3 and S4.
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Crystal Structure of Hepatitis B Virus e-Antigenat C48 and C107, which do not form disulfide bridges (Wingfield et al., 1995).
The HBeAg used for crystallization included the aforementioned mutations
plus G123A (Watts et al., 2011). HBeAg and Fab e6 were produced as previ-Structure 21, 133–142, January 8, 2013ously described (Watts et al., 2010), and to form
the complex, the components were mixed at
an expected stoichiometry of 1:2 (excess Fab
was removed by size-exclusion chromatography).
Crystallization trials were performed using the
sitting drop vapor diffusion method at a protein
concentration of 5.3 mg ml1 in 20 mM HEPES
pH 8.0 at 21C. Sitting drops were formed by
mixing 100 nl of protein solution and 100 nl of
reservoir solution (Walter et al., 2005). Plate-
shaped crystals were grown using reservoir solu-
tion containing 20% PEG 6000 and 100 mM bicine
pH 9.0. Rod-like crystals of Fab e6 crystals seren-
dipitously grew from a preparation of the complex
from which excess Fab had not been removed in
reservoir solution containing 20% PEG 3350,
100 mM bis-Tris propane pH 6.5, and 200 mM
potassium thiocyanate.
Structure Solution and Analysis
Diffraction data for HBeAg-e6 complex and Fab e6
were collected using synchrotron radiation from
single crystals to a resolution of 3.3 A˚ and 2.5 A˚,
respectively. The data were integrated and scaled
using xia2 (Winter, 2010). Initial phase informa-
tion for the Fab e6 data were obtained via an
automated Phaser (1994) molecular replacement
(MR) search using a Fab structure library (Stanfield
et al., 2006). Positional, TLS, and individual
isotropic B-factor refinement on the Fab e6 struc-
ture were carried out in BUSTER (Bricogne et al.,
2011) using fourfold NCS-restraints, followed by
iterative rebuilding of the hypervariable loops and
correction of the sequence. This Fab e6 structure,
refined against 2.5 A˚ resolution data, was used as
an MR model to obtain initial phase estimates for
theHBeAg-Fab e6 data. Positional, group B-factor
(one group per residue), TLS refinement were used
for structural refinement, with twofold NCS-
restraints and local structure similarity restraints
(LSSR) to the Fab structure applied to mitigate
the limited resolution of the data (Smart et al.,
2008). The Molprobity server (Chen et al., 2010)
and validation tools in Coot (Emsley et al., 2010)informed the quality of the structure refinement process. Refinement statistics
are given in Table 1, and final refined coordinates and structure factors
have been deposited for Fab e6 and HBeAg-Fab e6 with the Proteinª2013 Elsevier Ltd All rights reserved 139
Figure 5. Antigenic Switching of HBV Capsid Protein
HBcAg and HBeAg polypeptides share the same monomer fold. When
HBcAg dimerizes, an intermolecular disulfide bridge forms between C61 of
each subunit. In the HBeAg dimer, however, two intramolecular disulfides
form between C61 and propeptide residue C(7). Once locked into place,
the propeptides block HBcAg dimer formation. Instead, the HBeAg
subunits dimerize in an entirely different quaternary arrangement. As a result,
HBeAg dimers cannot form the dimer-dimer contacts employed in capsid
assembly. The molecular switch also explains how HBeAg and HBcAg are
antigenically distinct: surfaces presenting conformational epitopes on HBcAg
(dark blue) are altered in HBeAg (light blue) and antibody-inaccessible
surfaces on the interior of capsids are exposed in HBeAg (green). Antibodies
that bind to only one subunit within the shared surfaces (light and dark blue)
may be cross-reactive for both antigens. If HBeAg is subjected to reducing
conditions in vitro, these disulfides are disrupted and capsid-like assemblies
can form.
Structure
Crystal Structure of Hepatitis B Virus e-AntigenData Bank (PDB) with accession codes 3V6F and 3V6Z, respectively. PISA
interface web server was utilized for buried surface area and interacting
residue analysis of the HBeAg dimer interface and the HBeAg-Fab e6
epitope-paratope interface (Krissinel and Henrick, 2007). The Rapido server
was used to determine structurally similar subdomains within HBeAg and
HBcAg monomers (Mosca et al., 2008). Secondary structure assignment of
HBeAg was done using DSSP (Kabsch and Sander, 1983) and Stride (Heinig
and Frishman, 2004). Molecular graphics were produced using Pymol (DeLano
Scientific).
Sedimentation Velocity Analysis and Negative-Stain Electron
Microscopy
HBeAg was dialyzed against PBS pH 7.2, plus 300 mM NaCl (total NaCl
450 mM). A sample treated with 10 mM DTT was also dialyzed against the
same buffer, plus 2 mM DTT. Under either of these conditions, dimeric HBcAg
(Cp149) readily and efficiently forms capsids. Following dialysis for 24 hr,
samples were analyzed by sedimentation velocity. Measurement of the height
(UV absorbance) of the sedimenting boundaries allows the concentrations of
the various species to be determined. The oxidized and reduced HBeAg
samples were also applied to glow-discharged, poly-lysine coated carbon
grids at a concentration of 0.25 mg/ml, stained with 1% uranyl acetate,
and observed at 335,000 magnification in a Philips CM-120 electron
microscope.140 Structure 21, 133–142, January 8, 2013 ª2013 Elsevier Ltd All rigACCESSION NUMBERS
The PDB accession numbers for the atomic coordinates and structure factors
for HBeAg-e6 Fab and e6 Fab are 3V6F and 3V6Z, respectively.SUPPLEMENTAL INFORMATION
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